Published in Hum Mol Genet on May 22, 2006
RNA and disease. Cell (2009) 7.98
Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science (2009) 3.62
A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A (2008) 3.33
Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell (2007) 3.26
Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell (2012) 3.20
Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A (2006) 3.09
Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol (2010) 3.07
An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet (2011) 2.99
Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. Nucleic Acids Res (2007) 2.95
Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet (2006) 2.86
Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest (2007) 2.68
Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature (2012) 2.63
MBNL binds similar RNA structures in the CUG repeats of myotonic dystrophy and its pre-mRNA substrate cardiac troponin T. RNA (2007) 2.58
The pathobiology of splicing. J Pathol (2010) 2.52
RNA gain-of-function in spinocerebellar ataxia type 8. PLoS Genet (2009) 2.45
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.32
Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans (2009) 2.32
Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.21
Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest (2007) 2.14
C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis and frontotemporal dementia forms RNA G-quadruplexes. Sci Rep (2012) 2.09
Cellular toxicity of expanded RNA repeats: focus on RNA foci. Hum Mol Genet (2011) 2.05
Structural insights into RNA recognition by the alternative-splicing regulator muscleblind-like MBNL1. Nat Struct Mol Biol (2008) 2.00
Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci U S A (2008) 1.94
Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov (2011) 1.89
Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet (2009) 1.80
Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron (2012) 1.78
Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J Am Chem Soc (2008) 1.70
Regulation of alternative splicing by the core spliceosomal machinery. Genes Dev (2011) 1.60
The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy. J Cell Biol (2013) 1.45
Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. J Am Chem Soc (2012) 1.44
CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet (2010) 1.44
Global regulation of alternative splicing during myogenic differentiation. Nucleic Acids Res (2010) 1.39
The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacol Rev (2015) 1.38
High frequency of co-segregating CLCN1 mutations among myotonic dystrophy type 2 patients from Finland and Germany. J Neurol (2008) 1.37
Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel. Hum Mol Genet (2011) 1.37
CUGBP1 and MBNL1 preferentially bind to 3' UTRs and facilitate mRNA decay. Sci Rep (2012) 1.35
Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet (2010) 1.35
Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res (2011) 1.29
The unstable repeats--three evolving faces of neurological disease. Neuron (2013) 1.26
Genetic and chemical modifiers of a CUG toxicity model in Drosophila. PLoS One (2008) 1.25
Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol (2013) 1.22
In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models. Proc Natl Acad Sci U S A (2011) 1.22
Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease. Mol Cell (2014) 1.21
Neuronal regulation of pre-mRNA splicing by polypyrimidine tract binding proteins, PTBP1 and PTBP2. Crit Rev Biochem Mol Biol (2012) 1.20
Compound loss of muscleblind-like function in myotonic dystrophy. EMBO Mol Med (2013) 1.19
Muscleblind-like proteins: similarities and differences in normal and myotonic dystrophy muscle. Am J Pathol (2008) 1.17
Defining early steps in mRNA transport: mutant mRNA in myotonic dystrophy type I is blocked at entry into SC-35 domains. J Cell Biol (2007) 1.16
Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients. J Transl Med (2010) 1.13
MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1. Nucleic Acids Res (2009) 1.13
Expression of RNA CCUG repeats dysregulates translation and degradation of proteins in myotonic dystrophy 2 patients. Am J Pathol (2009) 1.12
RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity. Brain Res (2012) 1.11
From dynamic combinatorial 'hit' to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy. Nucleic Acids Res (2012) 1.10
The RNA-binding protein Staufen1 is increased in DM1 skeletal muscle and promotes alternative pre-mRNA splicing. J Cell Biol (2012) 1.09
Alternative splicing dysregulation secondary to skeletal muscle regeneration. Ann Neurol (2011) 1.09
Myotonic dystrophy. Neurol Clin (2014) 1.08
Selective silencing of mutated mRNAs in DM1 by using modified hU7-snRNAs. Nat Struct Mol Biol (2010) 1.08
Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms. Curr Genomics (2010) 1.07
Myotonic dystrophy mouse models: towards rational therapy development. Trends Mol Med (2011) 1.07
New function for the RNA helicase p68/DDX5 as a modifier of MBNL1 activity on expanded CUG repeats. Nucleic Acids Res (2011) 1.06
Prediction of clustered RNA-binding protein motif sites in the mammalian genome. Nucleic Acids Res (2013) 1.05
The impact of alternative splicing in vivo: mouse models show the way. RNA (2007) 1.03
Cytoplasmic CUG RNA foci are insufficient to elicit key DM1 features. PLoS One (2008) 1.01
Pathogenic RNAs in microsatellite expansion disease. Neurosci Lett (2009) 1.01
Novel transcriptional profile in wrist muscles from cerebral palsy patients. BMC Med Genomics (2009) 1.01
Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1. ACS Chem Biol (2012) 1.01
Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies. Acta Myol (2013) 1.01
Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus. PLoS Genet (2012) 1.01
RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy. Mol Ther (2012) 1.00
MBNL proteins and their target RNAs, interaction and splicing regulation. Nucleic Acids Res (2014) 1.00
Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins. Genome Res (2015) 1.00
The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches. EMBO Rep (2015) 0.99
Drosophila muscleblind is involved in troponin T alternative splicing and apoptosis. PLoS One (2008) 0.99
Ribonuclear foci at the neuromuscular junction in myotonic dystrophy type 1. Neuromuscul Disord (2007) 0.98
Common variants near MBNL1 and NKX2-5 are associated with infantile hypertrophic pyloric stenosis. Nat Genet (2012) 0.98
CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease. Mol Cell Neurosci (2012) 0.98
Altered RNA splicing contributes to skeletal muscle pathology in Kennedy disease knock-in mice. Dis Model Mech (2009) 0.97
Myotonic dystrophy: therapeutic strategies for the future. Neurotherapeutics (2008) 0.96
Targeting toxic RNAs that cause myotonic dystrophy type 1 (DM1) with a bisamidinium inhibitor. J Am Chem Soc (2014) 0.96
RNA splicing is responsive to MBNL1 dose. PLoS One (2012) 0.96
Muscleblind-like 1 (Mbnl1) regulates pre-mRNA alternative splicing during terminal erythropoiesis. Blood (2014) 0.95
The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression. Cell Rep (2014) 0.95
Mouse model of muscleblind-like 1 overexpression: skeletal muscle effects and therapeutic promise. Hum Mol Genet (2012) 0.95
Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2. Acta Neuropathol (2010) 0.94
Analysis of exonic regions involved in nuclear localization, splicing activity, and dimerization of Muscleblind-like-1 isoforms. J Biol Chem (2011) 0.94
Autoregulated splicing of muscleblind-like 1 (MBNL1) Pre-mRNA. J Biol Chem (2011) 0.94
Cell-free cloning of highly expanded CTG repeats by amplification of dimerized expanded repeats. Nucleic Acids Res (2008) 0.92
Molecular mechanisms of muscle atrophy in myotonic dystrophies. Int J Biochem Cell Biol (2013) 0.91
The neurogenetics of alternative splicing. Nat Rev Neurosci (2016) 0.91
Mechanisms of RNA-induced toxicity in CAG repeat disorders. Cell Death Dis (2013) 0.91
Epigenetic changes and non-coding expanded repeats. Neurobiol Dis (2010) 0.91
RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2. Am J Pathol (2011) 0.91
Altered expression and splicing of Ca(2+) metabolism genes in myotonic dystrophies DM1 and DM2. Neuropathol Appl Neurobiol (2013) 0.88
Features of modularly assembled compounds that impart bioactivity against an RNA target. ACS Chem Biol (2013) 0.88
Evaluating the effects of CELF1 deficiency in a mouse model of RNA toxicity. Hum Mol Genet (2013) 0.87
Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy. Front Mol Neurosci (2014) 0.87
Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy. Nat Commun (2016) 0.87
Expression of a dominant negative CELF protein in vivo leads to altered muscle organization, fiber size, and subtype. PLoS One (2011) 0.86
High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines. Hum Mol Genet (2013) 0.86
Myotonic dystrophy: is a narrow focus obscuring the rest of the field? Curr Opin Neurol (2012) 0.86
Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. Nucleic Acids Res (2015) 0.86
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
A muscleblind knockout model for myotonic dystrophy. Science (2003) 5.93
Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell (2002) 4.44
Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol (2011) 4.09
Muscleblind proteins regulate alternative splicing. EMBO J (2004) 4.01
Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science (2009) 3.62
Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A (2010) 3.58
Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet (2004) 3.21
Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A (2006) 3.09
Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol (2010) 3.07
Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature (2013) 3.00
Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. Nucleic Acids Res (2007) 2.95
Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr (2009) 2.90
Essential role for Dicer during skeletal muscle development. Dev Biol (2007) 2.76
Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest (2007) 2.68
Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature (2012) 2.63
RNA gain-of-function in spinocerebellar ataxia type 8. PLoS Genet (2009) 2.45
MicroRNA, mRNA, and protein expression link development and aging in human and macaque brain. Genome Res (2010) 2.44
Gene expression profile of aging in human muscle. Physiol Genomics (2003) 2.36
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.32
Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J Cell Sci (2005) 2.31
Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.21
Dual requirement for yeast hnRNP Nab2p in mRNA poly(A) tail length control and nuclear export. EMBO J (2002) 2.07
Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc (2009) 2.06
Chloride channelopathy in myotonic dystrophy resulting from loss of posttranscriptional regulation for CLCN1. Am J Physiol Cell Physiol (2006) 2.02
Skeletal muscle gene expression profiles in 20-29 year old and 65-71 year old women. Exp Gerontol (2004) 2.00
RNA-dominant diseases. Hum Mol Genet (2006) 2.00
Oxidized LDL downregulates ATP-binding cassette transporter-1 in human vascular endothelial cells via inhibiting liver X receptor (LXR). Cardiovasc Res (2005) 1.99
Small molecule regulators of protein arginine methyltransferases. J Biol Chem (2004) 1.99
Dynamic balance between activation and repression regulates pre-mRNA alternative splicing during heart development. Dev Dyn (2005) 1.95
Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol (2007) 1.91
Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clin Infect Dis (2011) 1.87
Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J Gen Physiol (2006) 1.83
Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. Nat Genet (2013) 1.80
Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet (2009) 1.80
Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron (2012) 1.78
Sarcolemmal-restricted localization of functional ClC-1 channels in mouse skeletal muscle. J Gen Physiol (2010) 1.73
Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J Am Chem Soc (2008) 1.70
Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol (2007) 1.61
Mechanisms of RNA-mediated disease. J Biol Chem (2008) 1.59
Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet (2003) 1.59
Nuclear RNA foci in the heart in myotonic dystrophy. Circ Res (2005) 1.57
Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol (2003) 1.56
Perilipin 5 improves hepatic lipotoxicity by inhibiting lipolysis. Hepatology (2015) 1.55
Controlling the specificity of modularly assembled small molecules for RNA via ligand module spacing: targeting the RNAs that cause myotonic muscular dystrophy. J Am Chem Soc (2009) 1.54
Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling. Circulation (2012) 1.51
Muscle growth after postdevelopmental myostatin gene knockout. Am J Physiol Endocrinol Metab (2006) 1.49
Developmental expression of mouse muscleblind genes Mbnl1, Mbnl2 and Mbnl3. Gene Expr Patterns (2003) 1.49
Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues. Hum Mol Genet (2010) 1.46
Computational method for reducing variance with Affymetrix microarrays. BMC Bioinformatics (2002) 1.44
Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in cancer: a meta-analysis. Gene (2012) 1.44
Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. J Am Chem Soc (2012) 1.44
The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol (2010) 1.44
Helicobacter pylori detection by polymerase chain reaction in pediatric gastritis. J Pediatr Gastroenterol Nutr (2012) 1.43
Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem Biol (2012) 1.43
Quantitative analysis of hemoglobin content in polymeric nanoparticles as blood substitutes using Fourier transform infrared spectroscopy. J Mater Sci Mater Med (2010) 1.41
Molecular pharmacognosy: a new borderline discipline. Nat Prod Commun (2009) 1.39
Cancer risk among patients with myotonic muscular dystrophy. JAMA (2011) 1.38
Hydrodynamics of biological aggregates of different sludge ages: an insight into the mass transport mechanisms of bioaggregates. Environ Sci Technol (2003) 1.38
Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel. Hum Mol Genet (2011) 1.37
Partners in crime: bidirectional transcription in unstable microsatellite disease. Hum Mol Genet (2010) 1.37
Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials (2009) 1.35
Intergenic and repeat transcription in human, chimpanzee and macaque brains measured by RNA-Seq. PLoS Comput Biol (2010) 1.33
Design and testing of a microfluidic biochip for cytokine enzyme-linked immunosorbent assay. Biomicrofluidics (2009) 1.33
Clinical and genetic heterogeneity in progressive external ophthalmoplegia due to mutations in polymerase gamma. Arch Neurol (2003) 1.29
Genotypic variants at 2q33 and risk of esophageal squamous cell carcinoma in China: a meta-analysis of genome-wide association studies. Hum Mol Genet (2012) 1.28
Extension of cortical synaptic development distinguishes humans from chimpanzees and macaques. Genome Res (2012) 1.27
Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve (2007) 1.23
Widespread splicing changes in human brain development and aging. Mol Syst Biol (2013) 1.23
Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol (2013) 1.22
Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control (2009) 1.22
Sex-related differences in gene expression in human skeletal muscle. PLoS One (2008) 1.20
Myosin light chain phosphorylation is critical for adaptation to cardiac stress. Circulation (2012) 1.19
Compound loss of muscleblind-like function in myotonic dystrophy. EMBO Mol Med (2013) 1.19
Bidirectional transcription stimulates expansion and contraction of expanded (CTG)*(CAG) repeats. Hum Mol Genet (2010) 1.19
Gastric cancer incidence and mortality in Zhuanghe, China, between 2005 and 2010. World J Gastroenterol (2012) 1.19